...
首页> 外文期刊>Journal of bacteriology >Engineered Fatty Acid Biosynthesis inStreptomyces by Altered Catalytic Function of β-Ketoacyl-Acyl Carrier Protein Synthase III
【24h】

Engineered Fatty Acid Biosynthesis inStreptomyces by Altered Catalytic Function of β-Ketoacyl-Acyl Carrier Protein Synthase III

机译:β-酮酰基-酰基载体蛋白合酶III催化功能的改变,工程菌在链霉菌中的生物合成

获取原文
           

摘要

The Streptomyces glaucescens β-ketoacyl-acyl carrier protein (ACP) synthase III (KASIII) initiates straight- and branched-chain fatty acid biosynthesis by catalyzing the decarboxylative condensation of malonyl-ACP with different acyl-coenzyme A (CoA) primers. This KASIII has one cysteine residue, which is critical for forming an acyl-enzyme intermediate in the first step of the process. Three mutants (Cys122Ala, Cys122Ser, Cys122Gln) were created by site-directed mutagenesis. Plasmid-based expression of these mutants in S. glaucescens resulted in strains which generated 75 (Cys122Ala) to 500% (Cys122Gln) more straight-chain fatty acids (SCFA) than the corresponding wild-type strain. In contrast, plasmid-based expression of wild-type KASIII had no effect on fatty acid profiles. These observations are attributed to an uncoupling of the condensation and decarboxylation activities in these mutants (malonyl-ACP is thus converted to acetyl-ACP, a SCFA precursor). Incorporation experiments with perdeuterated acetic acid demonstrated that 9% of the palmitate pool of the wild-type strain was generated from an intact D3 acetyl-CoA starter unit, compared to 3% in a strain expressing the Cys122Gln KASIII. These observations support the intermediacy of malonyl-ACP in generating the SCFA precursor in a strain expressing this mutant. To study malonyl-ACP decarboxylase activity in vitro, the KASIII mutants were expressed and purified as His-tagged proteins in Escherichia coli and assayed. In the absence of the acyl-CoA substrate the Cys122Gln mutant and wild-type KASIII were shown to have comparable decarboxylase activities in vitro. The Cys122Ala mutant exhibited higher activity. This activity was inhibited for all enzymes by the presence of high concentrations of isobutyryl-CoA (>100 μM), a branched-chain fatty acid biosynthetic precursor. Under these conditions the mutant enzymes had no activity, while the wild-type enzyme functioned as a ketoacyl synthase. These observations indicate the likely upper and lower limits of isobutyryl-CoA and related acyl-CoA concentrations within S. glaucescens.
机译: glaucescens β-酮酰基-酰基载体蛋白(ACP)合酶III(KASIII)通过催化丙二酰-ACP与不同酰基辅酶A的脱羧缩合反应来引发直链和支链脂肪酸的生物合成。 (CoA)引物。该KASIII具有一个半胱氨酸残基,这对于在该方法的第一步中形成酰基酶中间体至关重要。通过定点诱变产生了三个突变体(Cys122Ala,Cys122Ser,Cys122Gln)。这些突变体在 S中基于质粒的表达。 glaucescens 产生的菌株比相应的野生型菌株多产生75(Cys122Ala)至500%(Cys122Gln)的直链脂肪酸(SCFA)。相反,野生型KASIII的基于质粒的表达对脂肪酸谱没有影响。这些观察结果归因于这些突变体中缩合和脱羧活性的解偶联(丙二酰基-ACP因此转化为乙酰基-ACP,SCFA前体)。掺入氘代乙酸的掺入实验表明,野生型菌株的棕榈酸酯库中有9%来自完整的D 3 乙酰辅酶A起始单位,而表达Cys122Gln的菌株中只有3% KASIII。这些观察结果支持丙二酰-ACP在表达该突变体的菌株中产生SCFA前体的中间性。为了研究丙二酰-ACP脱羧酶的体外活性,在大肠杆菌中将KASIII突变体表达并纯化为His标记蛋白并进行了分析。在没有酰基辅酶A底物的情况下,Cys122Gln突变体和野生型KASIII在体外具有相当的脱羧酶活性。 Cys122Ala突变体表现出更高的活性。高浓度的异丁酰基-CoA(> 100μM)(一种支链脂肪酸生物合成前体)的存在抑制了所有酶的这种活性。在这些条件下,突变酶没有活性,而野生型酶起酮酰基合酶的作用。这些观察结果表明 S内异丁酰-CoA和相关酰基-CoA浓度的可能上限和下限。 glaucescens

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号